서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Publications

Detailed Information

Neurochemical Alterations in Methamphetamine-Dependent Patients Treated with Cytidine-5 `-Diphosphate Choline: A Longitudinal Proton Magnetic Resonance Spectroscopy Study

DC Field Value Language
dc.contributor.authorYoon, Sujung J.-
dc.contributor.authorLyoo, In Kyoon-
dc.contributor.authorKim, Hengjun J.-
dc.contributor.authorKim, Tae-Suk-
dc.contributor.authorKim, Namkug-
dc.contributor.authorRenshaw, Perry F.-
dc.contributor.authorLukas, Scott E.-
dc.contributor.authorSung, Young Hoon-
dc.date.accessioned2012-07-04T08:43:51Z-
dc.date.available2012-07-04T08:43:51Z-
dc.date.issued2010-04-
dc.identifier.citationNEUROPSYCHOPHARMACOLOGY; Vol.35 5; 1165-1173ko_KR
dc.identifier.issn0893-133X-
dc.identifier.urihttps://hdl.handle.net/10371/78488-
dc.description.abstractCytidine-5`-diphosphate choline (CDP-choline), as an important intermediate for major membrane phospholipids, may exert neuroprotective effects in various neurodegenerative disorders. This longitudinal proton magnetic resonance spectroscopy ((1)H-MRS) study aimed to examine whether a 4-week CDP-choline treatment could alter neurometabolite levels in patients with methamphetamine (MA) dependence and to investigate whether changes in neurometabolite levels would be associated with MA use. We hypothesized that the prefrontal levels of N-acetyl-aspartate (NAA), a neuronal marker, and choline-containing compound (Cho), which are related to membrane turnover, would increase with CDP-choline treatment in MA-dependent patients. We further hypothesized that this increase would correlate with the total number of negative urine results. Thirty-one treatment seekers with MA dependence were randomly assigned to receive CDP-choline (n = 16) or placebo (n 15) for 4 weeks. Prefrontal NAA and Cho levels were examined using (1)H-MRS before medication, and at 2 and 4 weeks after treatment. Generalized estimating equation regression analyses showed that the rate of change in prefrontal NAA (p = 0.005) and Cho (p = 0.03) levels were greater with CDP-choline treatment than with placebo. In the CDP-choline-treated patients, changes in prefrontal NAA levels were positively associated with the total number of negative urine results (p = 0.03). Changes in the prefrontal Cho levels, however, were not associated with the total number of negative urine results. These preliminary findings suggest that CDP-choline treatment may exert potential neuroprotective effects directly or indirectly because of reductions in drug use by the MA-dependent patients. Further studies with a larger sample size of MA-dependent patients are warranted to confirm a long-term efficacy of CDP-choline in neuroprotection and abstinence. Neuropsychopharmacology (2010) 35, 1165-1173; doi: 10.1038/npp.2009.221; published online 30 December 2009ko_KR
dc.description.sponsorshipThis study was supported in part by grants from the NIDA
(1R01 DA024070-01A1, Drs Lyoo and Renshaw; 5 R01 DA
14178-05, Dr Renshaw), from the NIH (7K24DA015116,
Dr Renshaw; 5K05-DA000343-12, Dr Lukas), from the
Korean Ministry of Education, Science and Technology,
(2009K001272, Dr Lyoo; Basic Science Research Program
20090066915, Dr Yoon), and from Seoul National University
Hospital (03-2008-006-0, Dr Lyoo).		ko_KR
dc.language.isoenko_KR
dc.publisherNATURE PUBLISHING GROUPko_KR
dc.subjectcytidine-5 `-diphosphate cholineko_KR
dc.subjectN-acetyl-aspartateko_KR
dc.subjectmethamphetamine dependenceko_KR
dc.subjectproton magnetic resonance spectroscopyko_KR
dc.subjecttreatmentko_KR
dc.titleNeurochemical Alterations in Methamphetamine-Dependent Patients Treated with Cytidine-5 `-Diphosphate Choline: A Longitudinal Proton Magnetic Resonance Spectroscopy Studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor윤수정-
dc.contributor.AlternativeAuthor류인균-
dc.contributor.AlternativeAuthor김흥준-
dc.contributor.AlternativeAuthor김태석-
dc.contributor.AlternativeAuthor성영훈-
dc.contributor.AlternativeAuthor김남국-
dc.identifier.doi10.1038/npp.2009.221-
dc.citation.journaltitleNEUROPSYCHOPHARMACOLOGY-
dc.description.citedreferenceYoon SJ, 2009, NEUROPSYCHOPHARMACOL, V34, P1810, DOI 10.1038/npp.2009.2-
dc.description.citedreferenceTian CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005546-
dc.description.citedreferenceSilveri MM, 2008, NMR BIOMED, V21, P1066, DOI 10.1002/nbm.1281-
dc.description.citedreferenceBustillo JR, 2008, NEUROPSYCHOPHARMACOL, V33, P2456, DOI 10.1038/sj.npp.1301631-
dc.description.citedreferenceMathew SJ, 2008, BIOL PSYCHIAT, V63, P891, DOI 10.1016/j.biopsych.2007.09.012-
dc.description.citedreferenceBerman S, 2008, ANN NY ACAD SCI, V1141, P195, DOI 10.1196/annals.1441.031-
dc.description.citedreferenceLee NK, 2008, DRUG ALCOHOL REV, V27, P309, DOI 10.1080/09595230801919494-
dc.description.citedreferencePROVENCHER SW, 2008, LCMODEL USERS MANUAL-
dc.description.citedreference*DRUG ENF ADM, 2008, NAT DRUG THREAT ASS-
dc.description.citedreferenceChung A, 2007, INT J NEUROPSYCHOPH, V10, P765, DOI 10.1017/Sl461145706007395-
dc.description.citedreferenceBrown ES, 2007, J CLIN PSYCHOPHARM, V27, P498, DOI 10.1097/jcp.0b013e31814db4c4-
dc.description.citedreferenceScott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0-
dc.description.citedreferenceRadad K, 2007, INT J NEUROSCI, V117, P985, DOI 10.1080/10623320600934341-
dc.description.citedreferenceSalo R, 2007, BIOL PSYCHIAT, V61, P1272, DOI 10.1016/j.biopsych.2006.07.031-
dc.description.citedreferenceSung YH, 2007, DRUG ALCOHOL DEPEN, V88, P28, DOI 10.1016/j.drugalcdep.2006.09.011-
dc.description.citedreferenceVocci FJ, 2007, ADDICTION, V102, P96-
dc.description.citedreferenceHam BJ, 2007, EUR J NEUROSCI, V25, P324, DOI 10.1111/j.1460-9568.2006.05253.x-
dc.description.citedreferenceShearer J, 2007, J SUBST ABUSE TREAT, V32, P41, DOI 10.1016/j.jsat.2006.06.012-
dc.description.citedreference*DRUG ENF ADM, 2007, NAT DRUG THREAT ASS-
dc.description.citedreferenceSecades JJ, 2006, METHOD FIND EXP CLIN, V28, P1-
dc.description.citedreferenceHwang J, 2006, DRUG ALCOHOL DEPEN, V82, P177, DOI 10.1016/j.drugalcdep.2005.09.011-
dc.description.citedreferenceKim SJ, 2006, INT J NEUROPSYCHOPH, V9, P221, DOI 10.1017/S1461145705005699-
dc.description.citedreferenceGrohman K, 2006, BRAIN COGNITION, V60, P203-
dc.description.citedreferencePoling J, 2006, ARCH GEN PSYCHIAT, V63, P219-
dc.description.citedreferenceBae SC, 2006, DRUG ALCOHOL DEPEN, V81, P83, DOI 10.1016/j.drugalcdep.2005.05.016-
dc.description.citedreferenceQUINTON MS, 2006, AAPS J, V8, P337-
dc.description.citedreferenceKim SJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1383, DOI 10.1038/sj.npp.1300699-
dc.description.citedreferenceMeredith CW, 2005, HARVARD REV PSYCHIAT, V13, P141, DOI 10.1080/10673220591003605-
dc.description.citedreferenceNordahl TE, 2005, ARCH GEN PSYCHIAT, V62, P444-
dc.description.citedreferenceChang L, 2005, AM J PSYCHIAT, V162, P361-
dc.description.citedreferenceAdibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8-
dc.description.citedreference*NSDUH, 2005, RES 2005 NSUDH-
dc.description.citedreferenceBrown JM, 2003, PHARMACOL THERAPEUT, V99, P45, DOI 10.1016/S0163-7258(03)00052-4-
dc.description.citedreferenceBARREDA V, 2003, REV MUSEO ARGENTINO, V5, P215-
dc.description.citedreferenceBarrachina M, 2002, BRAIN RES, V957, P84-
dc.description.citedreferenceNordahl TE, 2002, PSYCHIAT RES-NEUROIM, V116, P43-
dc.description.citedreferenceRoss BM, 2002, DRUG ALCOHOL DEPEN, V67, P73-
dc.description.citedreferenceBabb SM, 2002, PSYCHOPHARMACOLOGY, V161, P248, DOI 10.1007/s00213-002-1045-y-
dc.description.citedreferenceRoss BM, 2002, PROSTAG LEUKOTR ESS, V66, P479, DOI 10.1054/plef.385-
dc.description.citedreferenceFIRST MB, 2002, STRUCTURAL CLIN INTE-
dc.description.citedreferenceClark WM, 2001, NEUROLOGY, V57, P1595-
dc.description.citedreferenceLukas SE, 2001, PSYCHOPHARMACOLOGY, V157, P163-
dc.description.citedreferenceDavidson C, 2001, BRAIN RES REV, V36, P1-
dc.description.citedreferenceMcLean MA, 2001, NEUROIMAGE, V14, P501, DOI 10.1006/nimg.2001.0827-
dc.description.citedreferenceSmith LM, 2001, NEUROLOGY, V57, P255-
dc.description.citedreferenceProvencher SW, 2001, NMR BIOMED, V14, P260-
dc.description.citedreferenceBertolino A, 2001, BIOL PSYCHIAT, V49, P39-
dc.description.citedreferenceWurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989-
dc.description.citedreferenceRawson RA, 2000, J PSYCHOACTIVE DRUGS, V32, P371-
dc.description.citedreferenceBoulanger Y, 2000, BRAIN RES REV, V33, P380-
dc.description.citedreferenceMoore GJ, 2000, BIOL PSYCHIAT, V48, P1-
dc.description.citedreferenceErnst T, 2000, NEUROLOGY, V54, P1344-
dc.description.citedreferenceWinsberg ME, 2000, BIOL PSYCHIAT, V47, P475-
dc.description.citedreferenceBluml S, 1999, MAGNET RESON MED, V42, P643-
dc.description.citedreferenceClement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643-
dc.description.citedreferenceRenshaw PF, 1999, PSYCHOPHARMACOLOGY, V142, P132-
dc.description.citedreferenceClark JB, 1998, DEV NEUROSCI-BASEL, V20, P271-
dc.description.citedreferenceDeicken RF, 1998, BIOL PSYCHIAT, V43, P483-
dc.description.citedreferenceAraki W, 1998, J NEUROSCI RES, V51, P667-
dc.description.citedreferenceMurray JB, 1998, J PSYCHOL, V132, P227-
dc.description.citedreferenceEllis CM, 1997, NEUROLOGY, V49, P438-
dc.description.citedreferenceHussain T, 1997, CLIN EXP HYPERTENS, V19, P131-
dc.description.citedreferenceChristensen JD, 1996, MAGNET RESON MED, V35, P658-
dc.description.citedreferenceReid MS, 1996, J PHARMACOL EXP THER, V276, P1244-
dc.description.citedreferenceROSS K, 1996, PARALLAX, V2, P67-
dc.description.citedreferenceDESTEFANO N, 1995, MAGNET RESON MED, V34, P721-
dc.description.citedreferenceVIAL D, 1995, J NEUROCHEM, V64, P2765-
dc.description.citedreferenceHOLSHOUSER BA, 1995, MAGNET RESON MED, V33, P589-
dc.description.citedreferenceWEISS GB, 1995, LIFE SCI, V56, P637-
dc.description.citedreferenceVIONDURY J, 1995, LANCET, V345, P60-
dc.description.citedreferenceDAVIE CA, 1994, BRAIN, V117, P49-
dc.description.citedreferenceMACKAY S, 1993, BIOL PSYCHIAT, V34, P261-
dc.description.citedreferenceMCALLISTER G, 1993, FEBS LETT, V324, P81-
dc.description.citedreferenceBARKER PB, 1993, NMR BIOMED, V6, P89-
dc.description.citedreferenceOMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881-
dc.description.citedreferenceWANG AM, 1990, AM J NEURORADIOL, V11, P1141-
dc.description.citedreferenceZEGER SL, 1986, BIOMETRICS, V42, P121-
dc.description.citedreferenceTRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658-
dc.description.citedreferenceSALIGAUT C, 1985, METHOD FIND EXP CLIN, V7, P5-
dc.description.citedreferenceAGUT J, 1984, NEUROPHARMACOLOGY, V23, P1403-
dc.description.citedreferenceALBERGHINA M, 1981, J NEUROSCI RES, V6, P421-
dc.description.citedreferencePATEL TB, 1979, BIOCHEM J, V184, P539-
dc.description.citedreferenceMARTINET M, 1979, ARCH INT PHARMACOD T, V239, P52-
dc.description.citedreferenceMARTINET M, 1978, EXPERIENTIA, V34, P1197-
dc.description.citedreferenceHAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56-
dc.description.citedreferenceKENNEDY EP, 1956, J BIOL CHEM, V222, P193-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

Show Simple Item Record
Find it @ SNU

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share

qrcode
SNS Share